08 Dec 2021

TRP - Targeted Radiopharmaceuticals Summit 2021

The Goldilocks Criteria - Rationale for antibody fragments in radiopharmaceutical therapy

Gareth Smith, General Manager, Europe (December 8th at 10.30 CET)

Radiopharmaceutical Therapy (or RPT) is gaining significant research interest. Many of the agents focused on delivering RPT to date have focused on small molecules (including peptides) or intact antibodies. In his talk, Gareth will explore the utility of antibody fragment technologies to deliver RPT. In addition, he will look at how antibody fragments such as nanobodies, diabodies, and minibodies offer the potential to deliver optimal pharmacokinetics for RPT payload delivery through intermediate and tuneable blood clearance, tumor penetration and tumor uptake when compared with equivalent small molecules or antibodies to a tumor target while also exploring recent developments in the field of antibody fragments with a particular focus on “ The Goldilocks Criteria” and how this broad class of compounds could be just right for the future of RPT in cancer

Click here to find out more and register